297 related articles for article (PubMed ID: 31297240)
1. Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion.
Berghoff AS; Bellosillo B; Caux C; de Langen A; Mazieres J; Normanno N; Preusser M; Provencio M; Rojo F; Wolf J; Zielinski CC
ESMO Open; 2019; 4(3):e000498. PubMed ID: 31297240
[TBL] [Abstract][Full Text] [Related]
2. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155
[No Abstract] [Full Text] [Related]
3. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
Remon J; Hendriks LE; Cabrera C; Reguart N; Besse B
Cancer Treat Rev; 2018 Dec; 71():47-58. PubMed ID: 30359792
[TBL] [Abstract][Full Text] [Related]
4. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
5. Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
Ferrara MG; Di Noia V; D'Argento E; Vita E; Damiano P; Cannella A; Ribelli M; Pilotto S; Milella M; Tortora G; Bria E
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32397295
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
7. Oncogene-addicted non-small cell lung cancer and immunotherapy.
Tsakonas G; Ekman S
J Thorac Dis; 2018 May; 10(Suppl 13):S1547-S1555. PubMed ID: 29951305
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma.
Bylicki O; Guisier F; Monnet I; Doubre H; Gervais R; Janicot H; Perol M; Fournel P; Lamy R; Auliac JB; Chouaid C
Medicine (Baltimore); 2020 Jan; 99(3):e18726. PubMed ID: 32011450
[TBL] [Abstract][Full Text] [Related]
9. Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review.
McMahon DJ; McLaughlin R; Naidoo J
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339280
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study.
Guo X; Du H; Li J; Yang M; Xiong A; Zhang H; Wu F
Cancer Drug Resist; 2022; 5(1):15-24. PubMed ID: 35582532
[No Abstract] [Full Text] [Related]
11. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
12. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
Ke L; Xu M; Jiang X; Sun X
Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
[TBL] [Abstract][Full Text] [Related]
13. The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era.
Spagnuolo A; Muto M; Monaco F; Colantuoni G; Gridelli C
Transl Lung Cancer Res; 2019 Dec; 8(6):1134-1151. PubMed ID: 32010591
[TBL] [Abstract][Full Text] [Related]
14. Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer.
Lin JJ; Chin E; Yeap BY; Ferris LA; Kamesan V; Lennes IT; Sequist LV; Heist RS; Mino-Kenudson M; Gainor JF; Shaw AT
J Thorac Oncol; 2019 Jan; 14(1):135-140. PubMed ID: 30205166
[TBL] [Abstract][Full Text] [Related]
15. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.
Nagano T; Tachihara M; Nishimura Y
Curr Cancer Drug Targets; 2019; 19(8):595-630. PubMed ID: 30526458
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis.
Guaitoli G; Tiseo M; Di Maio M; Friboulet L; Facchinetti F
Transl Lung Cancer Res; 2021 Jun; 10(6):2890-2916. PubMed ID: 34295687
[TBL] [Abstract][Full Text] [Related]
17. Role of Immune Checkpoint Inhibitor Therapy in Advanced
Wiest N; Majeed U; Seegobin K; Zhao Y; Lou Y; Manochakian R
Front Oncol; 2021; 11():751209. PubMed ID: 34868953
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.
Guisier F; Dubos-Arvis C; Viñas F; Doubre H; Ricordel C; Ropert S; Janicot H; Bernardi M; Fournel P; Lamy R; Pérol M; Dauba J; Gonzales G; Falchero L; Decroisette C; Assouline P; Chouaid C; Bylicki O
J Thorac Oncol; 2020 Apr; 15(4):628-636. PubMed ID: 31945494
[TBL] [Abstract][Full Text] [Related]
19. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
20. The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas.
Rossi G; Graziano P; Leone A; Migaldi M; Califano R
Semin Diagn Pathol; 2013 Nov; 30(4):298-312. PubMed ID: 24342286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]